Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overreaction to a minor revenue guidance decline. Its stock trades at a significant discount to its peers despite growing faster than all but one.
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Accolade, Inc. (NASDAQ:ACCD ) Q2 2025 Earnings Conference Call October 8, 2024 8:00 AM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Jeff Garro - Stephens Inc. Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jared Haase - William Blair Stephanie Davis - Barclays Allen Lutz - Bank of America Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Operator Ladies and gentlemen, thank you for standing by. Welcome to Accolade Second Quarter 2025 Earnings Results Conference Call.
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.
On October 8, 2024, Accolade Inc (ACCD, Financial) released its 8-K filing detailing the financial results for the fiscal second quarter ending August 31, 2024. Accolade Inc, a company offering technology-enabled solutions to navigate the healthcare system, reported a revenue of $106.4 million, exceeding the analyst estimate of $105.01 million.
Accolade Inc (ACCD, Financial) is set to release its Q2 2025 earnings on Oct 8, 2024. The consensus estimate for Q2 2025 revenue is $105.01 million, and the earnings are expected to come in at -$0.44 per share.
Accolade, Inc. ACCD will release earnings results for its second quarter, before the opening bell on Tuesday, Oct. 8.